Phase 2bData readout

Lomecel-B (laromestrocel)

Hypoplastic Left Heart Syndrome

LGVNLongeveron Inc

Expected catalystSeptember 30, 2026Company guidance: Sep 30, 2026

Catalyst overview

Event details

Drug or asset: Lomecel-B (laromestrocel)
Development stage: Phase 2b
Event type: Data readout
Indication: Hypoplastic Left Heart Syndrome

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome. The expected timing is based on the latest available company guidance and may change.

Development notes

05/13/26:- ELPIS II topline results remain expected in August 2026. 08/12/26:- ELPIS II Ph2b topline results are expected in September 2026; final DMC review found no safety concerns.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source